<div><div></div><div>Eton Pharmaceuticals entered into an exclusive U.S. supply and distribution agreement for the commercialization rights to IMPAVIDO (miltefosine). Eton will pay $4.25 million in fixed fees through March 31, 2032, plus up to $4.0 million in sales milestones, and will remit 55% of annual net sales up to $7.0 million and 50% above that. The Supplier will cover product and regulatory costs while Eton funds sales and marketing; exclusivity begins September 26, 2026. Symphony Health reported 2025 U.S. sales of $8.1 million.Agreement details:<ul><li>Agreement type: Exclusive U.S. commercialization supply and distribution agreement for IMPAVIDO</li><li>Counterparty: Knight Therapeutics (affiliate)</li><li>Signed / Effective: May 18 2026 / Sep 26 2026</li><li>Duration / Termination: Initial term to Mar 31 2032; up to ten 1-year renewals</li><li>Reason: Expand orphan drug portfolio with exclusive U.S. rights to IMPAVIDO</li></ul>Original SEC Filing: Eton Pharmaceuticals, Inc. [ ETON ] - 8-K - May. 19, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

ETON

SBIO

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million.

TradingView

Eton Pharmaceuticals

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share